Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. Pfizer is scheduled to release its 4Q17 earnings on January 30, 2018. For 4Q17, Wall Street analysts expect Pfizer to report an EPS (earnings per share) of $0.56 on revenues of $13.72 billion.
The above chart compares the revenues and EPS for Pfizer in the past few quarters.
4Q17 revenue estimates
Analysts expect Pfizer to report 0.6% growth in its 4Q17 revenues to $13.72 billion—compared to revenues of $13.63 billion during 4Q16. The revenues are expected to be driven by strong sales of key innovative health products like Ibrance, Xeljanz, and Xtandi. Lower sales of essential health products like Zyvox, Lyrica, Celebrex, and other established products could partially offset the growth during 4Q17.
For fiscal 2017, Wall Street analysts expect revenues of $52.55 billion—a 0.5% decline in revenue compared to $52.82 billion during 2016. The EPS is estimated at $2.59 during 2017—compared to an EPS of $2.40 during 2016.
Wall Street analysts expect the gross profit margin to increase 1.3% to 78.9% during 4Q17—compared to the gross profit margin of 77.6% in 4Q16. Due to increased research and development expenses, and increased selling, general, and administrative expenses, the EBITDA margin is expected to decrease to 34.5% during 4Q17—compared to the EBITDA margin of 38.1% during 4Q16. Pfizer’s net adjusted income is expected to increase to $3.34 billion during 4Q17—compared to the net adjusted income of $2.89 billion during 4Q16.